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carboxamide-1--D-ribofuranoside (AICAr) Transporters*
Received for publication, January 17, 2014, and in revised form, April 24, 2014 Published, JBC Papers in Press, April 28, 2014, DOI 10.1074/jbc.M114.551192
Johanna Ceschin‡§1, Christelle Saint-Marc‡§1, Jean Laporte‡§, Adrien Labriet‡§, Chloé Philippe‡§, Michel Moenner‡§,
Bertrand Daignan-Fornier‡§, and Benoît Pinson‡§2
From the ‡Université de Bordeaux IBGC UMR 5095 1, F-33077 Bordeaux, France and the §Centre National de la Recherche
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Background: AICAr is a potent anti-proliferative compound, but its cellular effects are poorly characterized.
Results: Yeast and human AICAr transporters were identified and found to be critical for AICAr sensitivity.
Conclusion: AICAr uptake in yeast and mammalian cells occurs through nucleoside transport systems.
Significance: AICAr uptake occurs differently in yeast and mammalian cells.
5-Aminoimidazole-4-carboxamide-1--D-ribofuranoside (AICAr)
is the precursor of the active monophosphate form (AICAR), a
small molecule with potent anti-proliferative and low energy
mimetic properties. The molecular bases for AICAR toxicity at
the cellular level are poorly understood. Here, we report the
isolation and characterization of several yeast AICAr-hypersen-
sitive mutants. Identification of the cognate genes allowed us to
establish that thiamine transporters Thi7 and Thi72 can effi-
ciently take up AICAr under conditions where they are overex-
pressed. We establish that, under standard growth conditions,
Nrt1, the nicotinamide riboside carrier, is the major AICAr
transporter in yeast. A study of AICAR accumulation in human
cells revealed substantial disparities among cell lines and con-
firmed that AICAr enters cells via purine nucleoside transport-
ers. Together, our results point to significant differences
between yeast and human cells for both AICAr uptake and
AICAR accumulation.
Amino-imidazole carboxamide ribonucleotide monophos-
phate (AICAR)3 is a precursor of AMP in the purine de novo
biosynthesis pathway and as such is naturally present in cells at
low concentrations (micro molar range) (1). At higher concen-
trations, AICAR is a potent low energy mimetic that stimulates
AMP-activated protein kinase (AMPK) by mimicking activa-
tion by AMP (2, 3). In vivo, this AMPK activating effect was
shown to increase the endurance of sedentarymice (4). Because
of its spectacular metabolic effects, AICAR is suspected to be
used as a doping agent and since 2011 appears on the list of
prohibited substances of the World Anti-Doping Agency. At
high concentrations, AICAR induces cell cycle arrest and/or
apoptosis (5). Importantly, it was found that AICAR-induced
apoptosis was higher in trisomic mouse embryonic fibroblasts
than in their euploid counterpart (6). Becausemost solid tumor
cells are aneuploid, i.e. have an incorrect number of chromo-
somes, AICAR is a promising anti-tumor molecule.
AICAR is provided tomammalian cells in its riboside precur-
sor form, AICAr, which is internalized and metabolized to
AICAR monophosphate (7). AICAr was proposed to enter the
cell through adenosine transporter(s) because its effects are
reversed by dipyridamole, an adenosine transporter inhibitor
(8, 9). The cognate AICAr transporters have not yet been iden-
tified. Once it has been internalized, AICAr is converted to its
5-monophosphate form by adenosine kinase (1, 10). Impor-
tantly, the effects of AICAr on mammalian cells are generally
fully reversed by inhibition of adenosine kinase activity with
drugs such as 5-iodotubercidin, establishing that, inmost cases,
AICAr has to be metabolized to AICAR monophosphate to be
active (as expected for an AMP-mimetic). Similarly, in yeast,
the AICAr-induced transcriptional effects are abolished by a
mutation in the adenosine kinase gene (ADO1), and AICAr
toxicity is eliminated when it cannot be metabolized to the
monophosphate form (1).
Although many effects of AICAR are at least partially depen-
dent on AMPK, in many cases the effects of AICAR are AMPK-
independent (11–15), suggesting the existence of additional
AICAR targets. Interestingly, in yeast the AMPKhomolog named
Snf1 appearsunaffectedbyAICAR(16).This likely reflects the fact
that Snf1, contrary to its mammalian counterparts, is activated by
ADPandnotAMP (17). Yeast is therefore a very promisingmodel
to identify newAICAR targets and decipher themolecular mech-
anisms connecting AICAR monophosphate accumulation to its
toxic effects. Here, we used a genetic approach to explore the
molecular bases of AICAr sensitivity in this simple eukaryotic
model. Our results revealed a link between AICAr sensitivity and
thiaminemetabolism and allowed us to identify Nrt1 as themajor
AICAr transporter in yeast.
EXPERIMENTAL PROCEDURES
YeastMedia and Strains—SD is a syntheticminimalmedium
containing 5% ammonium sulfate, 0.67% yeast nitrogen base
* This work was supported by Association de la Recherche contre le Cancer
Grant SFI-2012-120-5915 (to B. D.-F.) and a grant from Ligue contre le Can-
cer du Périgord (to M. M.).
1 Both authors contributed equally to this work.
2 To whom correspondence should be addressed: Institut de Biochimie et
Génétique Cellulaires, CNRS UMR 5095 1 rue C. Saint-Saëns CS 61390,
F-33077 Bordeaux, France. Tel.: 33-556-999-019; Fax: 33-556-999-059;
E-mail: benoit.pinson@ibgc.cnrs.fr.
3 The abbreviations used are: AICAR, 5-amino-4-imidazole carboxamide
ribonucleotide 5-phosphate; AICAr, 5-amino-4-imidazole carboxamide
ribonucleoside; AMPK, AMP-activated protein kinase; ATIC, AICAR-trans-
formylase IMP-cyclohydrolase; NmR, nicotinamide riboside; MEF, mouse
embryonic fibroblast.
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(Difco), 2% glucose. SDcasaW is SD medium supplemented
with 0.2% casamino acids (Difco) and tryptophan (0.2 mM).
When indicated, adenine (0.3 mM) and/or uracil (0.3 mM) were
added in SDcasaW medium, resulting in a medium named
SDcasaWA ( adenine), and SDcasaWAU ( adenine  ura-
cil). SC medium was prepared as described by Sherman et al.
(18). SC complete medium is SC medium supplemented with
adenine (0.3 mM), uracil (0.3 mM), histidine (0.06 mM), leucine
(0.4 mM), lysine (0.06 mM), and tryptophan (0.2 mM). Yeast
strains (see Table 1) belong to, or are derived from, a set of
disrupted strains isogenic to BY4741 or BY4742 purchased
fromEuroscarf.Multimutant strainswere obtained by crossing,
sporulation, and micromanipulation of meiosis progeny.
Cell Culture and Proliferation Assay—U87 (HTB-14) and
A549 (CCL-185) cells were from ATCC. SF188 and SF126 cells
were a generous gift from M. Czabanka (Charité Universitäts-
medizin, Berlin, Germany). NHA/TS cells were kindly provided
by K. Sasai and S. Tanaka (Hokkaido University, Sapporo,
Japan). Huh7 cells were given by E. Chevet (University of Bor-
deaux, France). Wild-type or knock-out mouse embryonic
fibroblasts (MEFs) for both AMPK1 and AMPK2 subunits
(AMPK1/2 KO) were generously provided by B. Viollet
(Cochin Institute, INSERM, Paris, France). The cells were
grown at 37 °C, 5% CO2 in complete medium: DMEM contain-
ing 4.5 g/liter glucose and supplemented with 10% FBS, L-glu-
tamine, and antibiotics. TheWST-1 cell proliferation assay was
performed in 96-well plates according to the manufacturer’s
instructions (Roche). Briefly, the cells were plated at 5,000 cells/
cm2 in 100 l of complete culture medium. After 24 h of incu-
bation, AICAr and/or inhibitors were added in freshmedium at
the indicated concentrations. WST-1 assay was performed
after 3 days.
Plasmids—The THI80 centromeric plasmid (p4878) was
obtained by PCR amplification of the THI80 gene using S288C
genomic DNA as template and oligonucleotides 3730 (5-
CGCGGATCCCAACAAATTAAAGCGGAGATC-3) and
3731 (5-CCGCTCGAGCCTTACTTTAGAATGATGACTT-
TAC-3). The PCR product was digested with BamHI andXhoI
and cloned in the pRS316 vector (19) digested with the same
restriction enzymes. Plasmids allowing expression of the THI7
or THI72 genes under the control of a tetracycline repressible
promoter were obtained by PCR amplification of the THI7 or
THI72 coding regions using S288C genomic DNA as template
and oligonucleotides 3176 (5-CGCGGATCCAATATGAGT-
TTCGGTAGTAAAG-3) and 3177 (5-CCAATGCATCTAA-
GCAGCTTTTTCACTGGC-3) for THI7 or oligonucleotides
3178 (5-CGCGGATCCATTATGAGTTTCGGTACGAGA-
ATC-3) and 3179 (5-CCAATGCATTTAGGCAATTTGTT-
TTTCACTGG-3) for THI72. PCR products were digested
with BamHI and NsiI and were cloned in the pCM189 vector
(tetProm, CEN, URA3) (20) digested with BamHI and PstI,
resulting in the tet-THI7 (p4678) and tet-THI72 (p4680) plas-
mids. The NRT1 overexpression plasmid p4926 (2, URA3)
was constructed by PCR amplification of NRT1 using S288C
genomic DNA as template and oligonucleotides 3825 (5-
CGCGGATCCCAAGACGGTTGGCAATAGGAG-3) and
3826 (5-CCGGAATTCCCCCACCGGATTCTCTTGC-3). The
PCRproduct was digestedwith BamHI and EcoRI and cloned in
the YEpLac195 vector (21) digested with the same restriction
enzymes. The NRT1 centromeric plasmid p4980 (CEN,URA3)
was obtained by transferring the BamHI/EcoRI fragment con-
taining NRT1 gene into YCpLac33 centromeric plasmid (21)
opened with the same restriction enzymes. Finally, the
THI7prom-LacZ fusion used for GAL experiments (p4884)
was obtained by PCR amplification of theTHI7 promoter using
S288C genomic DNA as template and oligonucleotides 3625
(5-CGCGGATCCTATGACCGTGTCAAGGCATCC-3) and
3626 (5-ACGTCTGCAGCATATTGATATAATGCAATTG-
GCTC-3). ThePCRproductwas digestedwithBamHI andPstI
and was cloned in the Yep367 vector (2, LEU2) (22) digested
with the same restriction enzymes.
Isolation of AICAr Hypersensitive Mutants—To obtain AICAr-
hypersensitive mutants, two ade16 ade17 ade8 his1 strains
(Y6986 and Y7242) were plated on SD casa WAU medium,
mutagenized with UV light for 20 s, and then grown for 72 h at
30 °C. The resulting clones (64,000) were then transferred by
replica plating on the same medium containing various AICAr
concentrations (1 or 2 mM at 30 °C and 0.5 or 1 mM at 37 °C).
Thereby, 27 AICAr hypersensitive mutants were isolated from
the two yeast strains (17 fromY6986 and 10 fromY7242), and 3
of thesemutantswere further studied. Eachmutantwas crossed
with an ade16 ade17 ade8 his1 strain, and the meiotic progeny
of the cross was phenotypically characterized. Genomic DNA
extraction from pools of AICAr-resistant and -sensitive spores
(see text for details) was carried out on cells grown to a final
density of 5  107 cells/ml, as recommended by the genomic
tips 100G kit supplier (Qiagen). Yeast genome resequencing
and bioinformatics analyseswere done byGATCBiotech (Kon-
stanz, Germany). Once identified, mutations of interest in the
mutant pools were verified on individual spores by Sanger
sequencing (GATC Biotech).
Metabolite Extraction and Separation by Liquid Chro-
matography—Extraction of yeast metabolites was performed
by the rapid filtration and ethanol boiling method as described
(23). For mammalian cells, each extraction was done from one
78.5-cm2 Petri dish containing subconfluent cells ( 105 cells/
cm2) grown in the complete medium. The cells were rapidly
washed with 5 ml of ice-cold PBS, and then extraction was per-
formed by incubation of cells for 5min in 5ml of ethanol (80%).
The suspensionwas then transferred into a glass tube and incu-
bated for 3 min at 80 °C. Samples were evaporated using a
rotavapor device. The residue was suspended in sterile water
(100 l/107cells), and insoluble particles were eliminated by
centrifugation (1 h, 4 °C, 21,000 g). For both yeast and mam-
malian cells, metabolite separation was performed on an
ICS3000 chromatography station (Dionex, Sunnyvale, CA)
using a CarboPac PA1 column (250 2 mm; Dionex) with the
50–800 mM acetate gradient in 50 mMNaOH described in Ref.
1. Peaks were identified by their retention time as well as by
co-injection with standards and/or their UV spectrum signa-
ture. Of note, intracellular AICAr concentration is hardly
measurable when adenosine kinase is present, and furthermore
it is often contaminated by external AICAr (especially true for
mammalian cells), so we routinely used AICAR accumulation
as readout of AICAr entry.
AICAr Uptake in Yeast and Human Cells
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AICAr Uptake—Yeast cells were exponentially grown (2
107 cells/ml) for 24 h before being harvested by centrifugation
(3,200 g, 2 min, 30 °C). The cells were then suspended (4–5
107 cells/ml) in 1 ml of uptake buffer (50 mM sodium citrate, pH
4.5, containing 2% glucose) prewarmed at 30 °C and were kept
under agitation at this temperature. Uptake was started by the
addition of [3H]AICAr (100 M final concentration; 925 MBq/
mmol; Hartmann analytic). As a function of time (up to 15 min),
aliquots (300 l of cell suspension) were harvested by filtration
(nitrocellulose membranes, 0.8 m; Millipore), filters were then
washed twice with 3 ml of cold water and dried, and the retained
radioactivity was determined by scintillation counting. AICAr
uptake (pmol/min/107 cells) was calculated by linear regression of
the [3H]AICAr incorporated as function of time.
MiscellaneousMethods—Yeast growth test and GAL assays
were performed as described in Refs. 24 and 25, respectively.
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FIGURE 1.AICAR accumulation and toxicity in yeast. A, addition of extracellular AICAr does not result in amassive intracellular AICAR accumulation in yeast.
After an overnight preculture, wild-type cells (Y175) were diluted and kept in exponential phase for 24 h in SDcasaWAU medium. External AICAr (5 mM) was
then added (red line) or not (blue line) for 20min, andmetabolites were extracted and separated by liquid chromatography (only the 60–65-min elution time
region of the chromatogram is presented). AICAR intracellular concentration was determined by measuring yeast cell volume as described (1). The inset
corresponds to a zoom of the indicated region. Internal AICAR values correspond to three independent extractions, and standard deviation is indicated. B,
schematic representation of purine and histidine pathways in yeast. Ade, adenine; Hypox, hypoxanthine; PM, plasma membrane; PRPP, 5-phosphoribosyl-1-
pyrophosphate. Only the enzymesmentioned in the text are shown (in blue). C, intracellular AICAR accumulation is strongly increased in the ade16 ade17 ade8
his1mutant. The cells (Y6986)were grown in SDcasaWAUmedium, treated (green line) or not (orange line) with AICAr (5mM, 20min), and themetaboliteswere
extracted and separated as in Fig. 1A. Internal AICAR values correspond to three independent extractions, and standard deviation is indicated. N.D., not
detectable.D, effect of external AICAr on growth of the ade8 his1 (Y2660) or ade16 ade17 ade8 his1 (Quadruple; Y6986) strains. The cells were grownovernight,
serially diluted, and spottedon SDcasaWAUmediumcontaining external AICAr. Plateswere imaged after an incubation of 2 days at the indicated temperature.
TABLE 1
Yeast strains
Strain name Genotype
BY4741 MATa his31 leu20 met150 ura30
BY4742 MAT his31 leu20 lys20 ura30
Y175 MATa his31 leu20 ura30
Y2660 MATa ade8::kanMX4 his1::kanMX4 his31 leu20 ura30
Y2950 MAT ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31 leu20 ura30
Y3188 MAT ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 ado1::LEU2 his31 leu20 ura30
Y6986 MAT ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y7242 MATa ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-URA3 leu20 ura30
Y7314 MAT pdc2 (L634S) ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y7321 MAT thi3 (S402F) ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y7506 MATa thi80 (L90P) ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-URA3 leu20 ura30
Y8750 MATa thi7::KanMX4 ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31 leu20 ura30
Y8755 MATa thi72::KanMX4 ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31 leu20 ura30
Y8843 MATa pdc2 (L634S) ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-URA3 leu20 ura30
Y8845 MAT thi80 (L90P) ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-URA3 leu20 ura30
Y8848 MATa thi3 (S402F) ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-URA3 leu20 ura30
Y9116 MAT nrt1::KanMX4 ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31 leu20 ura30 lys20
Y9188 MATa nrt1::KanMX4 thi7::KanMX4 thi72::KanMX4 ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31 leu20 ura30
Y9437 MATa thi80 (L90P) nrt1::KanMX4 ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-URA3 leu20 ura30
AICAr Uptake in Yeast and Human Cells
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Nicotinamide riboside (NmR) was prepared by dephosphory-
lation of nicotinamide mononucleotide (Sigma-Aldrich) as
described (26).
RESULTS
Accumulation of Intracellular AICAR in Yeast—We first
aimed at identifying experimental conditions allowing AICAR
accumulation in yeast. Clearly, addition of AICAr (the riboside
form) to the growth medium did not result in massive intracel-
lular AICAR (the monophosphate form) accumulation in a
wild-type yeast strain (Fig. 1A). This could be due to poor
uptake of AICAr, inefficient metabolization to the monophos-
phate form by Ado1 and/or to highly active metabolization of
AICAR to IMP by ATIC (AICAR transformylase IMP cyclohy-
drolase) (Fig. 1B). The latter possibility was evaluated by mon-
itoring AICAR accumulation in a quadruple ade16 ade17 ade8
his1mutant unable to synthesize AICAR and to further metab-
olize it to IMP, because it is blocked upstream and downstream
in the pathway (Fig. 1B). By contrast to the wild-type strain, in
the quadruple ade16 ade17 ade8 his1 mutant AICAr feeding
led to robust AICAR accumulation (Fig. 1C). This result shows
that yeast cells can take up external AICAr and accumulate
FIGURE 2. The S90P recessivemutation in the THI80 gene is responsible for AICAr hypersensitivity of the Y7506mutant strain. A, the thi80mutation is
genetically linked toAICAr sensitivity. The cellsweregrownovernight, serially diluted, and spottedonSDcasaWAUmediumcontainingexternalAICAr. Parental
strains ade16 ade17 ade8 his1 eithermutated (Y7506) or not (control, Y7242) in the THI80 gene, and six derived spores are shown. The plateswere imaged after
3 days at 37 °C.WT andmut, respectively, stand for wild-type (THI80) andmutated (thi80) versions of thiamine pyrophosphate kinase gene, as determined by
sequencing.B, the thi80 (S90P)mutation leading toAICAr sensitivity is recessive.Diploidade16ade17ade8his1 strainsmutated (thi80) or not (THI80) in thiamine
pyrophosphate kinase genewere grown, diluted, and spotted on SDcasaWAUmediumas in Fig. 2A.C, complementation by thewild-type THI80gene. Haploid
ade16 ade17 ade8 his1 strains (WT, Y7242; or thi80, Y7506) were transformedwith a centromeric plasmid expressing (THI80) or not (vector) a wild-type copy of
THI80. Transformants were grown, diluted, and spotted on SDcasaWAmedium as in Fig. 2A. In A–C, the plates were imaged after 3 days at 37 °C. D, schematic
representation of thiamine metabolism and resulting regulation of THI gene expression.
FIGURE3.Mutations inTHI3andPDC2 lead toAICAr sensitivity.AandB,mutations inTHI3 (A) andPDC2 (B) are linked toAICArhypersensitivity. Thecellswere
grown overnight, serially diluted, and spotted on SDcasaWAUmedium containing external AICAr. Strains correspond to ade16 ade17 ade8 his1 parental cells
mutated (thi3, Y7321; orpdc2, Y7314)ornot (control, Y6986) and toderived spores. Theplateswere imagedafter 3days at 30 °C.WTandmut, respectively, stand
for wild-type and mutated versions of either THI3 or PDC2 gene as determined by sequencing of the corresponding gene. C and D, mutations in THI3 (C) and
PDC2 (D) are haploinsufficient or semidominant. Diploid ade16 ade17 ade8 his1 strains each carrying the indicated combination of mutated (thi3 or pdc2) and
wild-type (THI3 or PDC2) alleles were grown, diluted, and spotted on SDcasaWAUmedium. The plates were imaged after 48 h at 30 °C.
AICAr Uptake in Yeast and Human Cells
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AICAR in strains lacking ATIC activity. Accordingly, AICAr
was toxic at high concentration in the ade16 ade17 ade8 his1
mutant but not in the ade8 his1 mutant that has wild-type
ATIC activity (Fig. 1D). Of note, for an unknown reason, AICAr
was significantly and reproducibly more toxic at 37 °C than at
30 °C (Fig. 1D). At low concentrations (up to 2 mM at 30 °C and
1 mM at 37 °C), the quadruple ade16 ade17 ade8 his1 mutant
was resistant to AICAr (Fig. 1D). These subtoxic concentra-
tions were hereafter used to isolate and characterize yeast
mutants that are hypersensitive to AICAr. The ade16 ade17
ade8 his1 yeast strain, which can accumulate AICAR, was
mutagenized, and several AICAr hypersensitive mutants that
grew poorly in the presence of low concentrations of AICAr
were isolated (see “Experimental Procedures” for details).
Three of thesemutants, corresponding to strainsY7314, Y7321,
and Y7506 (Table 1), were further studied and are presented
below.
AICAr-hypersensitive Mutants Are Affected in Thiamine
Metabolism—The Y7506 mutant strain, presenting a severe
growth defect in the presence of AICAr (Fig. 2A) was back-
crossed to an ade16 ade17 ade8 his1 strain. Among the spores
resulting from meiosis, AICAr hypersensitivity segregated 2:2
in nine tetrads, indicating that AICAr sensitivity of this mutant
is a monogenic character. Genomic DNA extracted from 10
AICAR hypersensitive spores was mixed and sequenced. In
parallel, the genomes of a mix of 7 spores showing wild-type
AICAr sensitivity were sequenced. Comparison of these
genome sequences to the S288c reference genome allowed us to
identify one single-nucleotide polymorphism only found in the
genome mix from AICAr sensitive spores. This single-nucleo-
tide polymorphism corresponded to a T269C mutation in the
THI80 gene, resulting in a leucine to proline substitution at
position 90 in the Thi80 protein. Sequencing of theTHI80 gene
in the parental strain and in the AICAr-sensitive mutant con-
firmed that thismutationwas indeed present in themutant and
absent in the control and was the only mutation in this open
reading frame. This L90P substitution was found in all 10
hypersensitive AICAr segregants and in none of the 7 spores
showing wild-type resistance to AICAr (see examples spores
1–6 in Fig. 2A). The mutation was clearly recessive (Fig. 2B),
and AICAr hypersensitivity could be complemented by the
wild-type THI80 gene carried on a centromeric plasmid (Fig.
2C).We conclude that the L90P substitution in Thi80 results in
hypersensitivity to AICAr in yeast cells. THI80 is an essential
gene encoding thiamine pyrophosphokinase the enzyme syn-
thesizing thiamine pyrophosphate from thiamine (Fig. 2D).
Because THI80 is essential for viability and because the muta-
tion is recessive, the L90P substitutionmost probably results in
a partial loss of function that confers hypersensitivity to AICAr.
Two additional AICAr hypersensitive mutants were charac-
terized by analogous methods. Genome sequencing revealed
that the Y7321 mutant strain carried a C1205T mutation
located in the THI3 gene that co-segregated perfectly with
AICAr hypersensitivity in 14 spores and in none of the 13
AICAr-insensitive spores (Fig. 3A). This mutation resulted in a
S402F substitution in Thi3, a regulatory protein that binds and
activates the Pdc2p and Thi2p transcription factors (Fig. 2D).
Finally, the Y7314 mutant strain was found to carry a T1901C
mutation in the PDC2 gene co-segregating with AICAr hyper-
sensitivity in 7 spores and in none of the 7 AICAr-insensitive
spores (Fig. 3B). Thismutation resulted in a L634S replacement
in Pdc2, a transcriptional factor activating the thiaminemetab-
olism regulon when thiamine pyrophosphate (the product of
Thi80) is scarce (Fig. 2D). Importantly the thi3 and pdc2
heterozygote strains were still partially sensitive to AICAr, sug-
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FIGURE4. Intracellular concentrationof thiamineandAICARarehigher in
the AICAr-hypersensitive mutants. A, metabolic analysis of AICAR and thi-
amine derivatives in the AICAr-sensitive mutants. After an overnight precul-
ture, cells were diluted and kept in exponential phase for 24 h in SDcasaWAU
medium containing AICAr (0.5 mM). Metabolites were then extracted and
separated by liquid chromatography. TPP, thiamine pyrophosphate. The
question mark corresponds to an unidentified peak. B, relative intracellular
content of thiamine and AICAR derivatives. Quantifications were determined
from at least three independent metabolite extractions and separations for
each strain (control, Y6986; thi80, Y7506; thi3, Y7321; pdc2, Y7314), and error
bars indicate variations to the mean. For each metabolite, content of the
control strain (blue bar)was set at 1.C, chemical structure of adenosine, AICAr,
NmR, and thiamine.D, AICAr uptake is strongly enhanced in the AICAr-hyper-
sensitivemutants. the cells were exponentially grown for 24 h in SDcasaWAU
medium, and [3H]AICAr uptake was determined from at least two indepen-
dent kinetics, as described under “Experimental Procedures.” The error bars
indicate variations to the mean. Control, Y6986; thi80, Y8845; thi3, Y7321;
pdc2, Y7314.
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gesting haploinsufficiency or semidominance (Fig. 3, C andD).
Identification of these three mutations thus revealed a
strong connection between thiaminemetabolism and AICAr
sensitivity.
Accumulation of AICAR and Thiamine in the AICAr-hyper-
sensitive Mutants—To get a better understanding of the mech-
anisms leading to AICAr hypersensitivity in these mutants, the
effects of AICAr on the thi80, thi3, and pdc2 mutant strains
were further examined by analytical chromatography. Mutant
and control strains showed similarmetabolic profiles except for
intracellular content of AICAR and thiamine derivatives (Fig. 4,
A and B). The major effect associated with AICAr addition in
the mutants compared with the control strain was accumula-
tion of AICAR monophosphate (Fig. 4, A and B). This result
indicates that the hypersensitivity of the three mutants to
AICAr is likely to be due to increased accumulation of the
monophosphate derivative, which is likely to be the toxic form,
as previously suggested by the absence of toxicity of AICAr in
an adenosine kinasemutant (1). Remarkably, the threemutants
accumulated thiamine (Fig. 4, A and B), whereas the thiamine
pyrophosphate level was reduced in the thi80 mutant in good
consistence with the role of Thi80 in thiaminemetabolism (Fig.
2D). Together, these results indicated that both thiamine and
AICAr uptake could be enhanced in thesemutants. Thiamine is
known to strongly interferewith adenosine uptake in yeast (27),
and AICAr is structurally close to adenosine (Fig. 4C) and is
metabolized by adenosine kinase (1). Hence, AICAr-hypersen-
sitive mutations could somehow increase AICAr uptake,
thereby exacerbating sensitivity to AICAr. Indeed, AICAr
uptake was strongly enhanced in the three mutant strains (Fig.
4D).We thus further examined howmutations affecting Thi80,
Thi3, and Pdc2 could impact on this process.
Overexpression of Thiamine Transporters Results in AICAr
Hypersensitivity—It should be stressed that thiamine pyro-
phosphate (the product of Thi80), Thi3, and Pdc2 play a major
regulating role on the transcriptional expression of the thia-
mine regulon (Fig. 2D), including the THI7 gene encoding the
major thiamine transporter (28). Mutations isolated in our
AICAr-hypersensitive mutant screen could therefore affect
expression of the thiamine regulon. Indeed, a lacZ fusion driven
by theTHI7promoterwas foundup-regulated in all three thi80,
thi3, and pdc2 AICAr-hypersensitive mutants (Fig. 5A).
Together our results showing stimulation of Thi7 expression
and concomitant accumulation of AICAR and thiamine in the
mutant cells pointed to a connection between thiamine and
AICAr uptake by Thi7. Accordingly, constitutive overexpres-
sion of the thiamine transporter Thi7 enhanced AICAr sensi-
tivity of the ade16 ade17 ade8 his1 yeast strain (Fig. 5B) and
AICARmonophosphate accumulation (Fig. 5C). Similar results
were obtained, although to a lesser extent, by overexpressing
Thi72, a paralog of Thi7 (Fig. 5, B and C). Finally, AICAR accu-
mulation was severely reduced in yeast cells treated with thia-
FIGURE 5. AICAR accumulation and toxicity correlates with thiamine
transporter expression and activity. A, THI7 expression is increased in
AICAr-sensitive mutants. The ade16 ade17 ade8 his1 cells (control, Y7242;
thi80, Y8845; thi3, Y8848; pdc2, Y8843) transformed with a THI7-LacZ fusion
plasmid (p4884) were grown in SC-U-Lmedium to A600 nm 1. Relative-Gal
activities were measured as described under experimental procedures and
aregivenusing theY7242 strain as reference (set upat 1).B, overexpressionof
thiamine transporter genes leads to AICAr hypersensitivity. The ade16 ade17
ade8 his1 (Y6986) strainwas transformedwith a plasmid allowing or not (vec-
tor) the overexpression of either THI7 (p4678) or THI72 (p4680) gene. Trans-
formants were diluted and spotted on SDcasaWAmedium containing or not
AICAr. The plates were imaged after 2 days at 30 °C. C, intracellular AICAR
accumulation is enhanced by overexpression of thiamine carriers. Transfor-
mants from Fig. 5Bwere grown and treatedwith AICAr (5mM) for 20min, and
metabolites were extracted and separated as in Fig. 1A. Internal AICAR values
correspond to three independent determinations, and error bars indicate
variations to the mean. AICAR content in the strain containing the empty
vector was set up at 1. D, treatment with inhibitors of thiamine transporters
severely affects AICAR accumulation. Intracellular AICAR content was deter-
mined on metabolites extracts from ade16 ade17 ade8 his1 cells (Y6986)
grown in SDcasaWAUmedium and incubated for 20min with external AICAr
(5mM) as in Fig. 1A. Chloroquine (CQ, 2mM)or amodiaquine (AQ, 100M)were
added 1 min before AICAr addition. The results correspond to at least four
independent metabolite extractions, and error bars indicate variations to the
mean. AICAR content found in absence of inhibitor was set up at 1. E, chloro-
quine abolishes AICAr sensitivity of thi80 and pdc2 mutants. The cells were
grown overnight, serially diluted, and spotted on SDcasaWAU medium con-
taining external AICAr (5 mM) and supplemented or not with chloroquine (2
mM). The plates were imaged after 2 days at 30 °C.
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mine uptake inhibitors (chloroquine and amodiaquine) (29)
(Fig. 5D), and AICAR toxicity in vivo was abolished by chloro-
quine (Fig. 5E). Together, our data show that increased expres-
sion of the thiamine transporters Thi7 and its paralog Thi72
results in robust stimulation of AICAr uptake in yeast cells. In
addition, our results establish that AICAr uptake is limiting for
AICAR toxicity in yeast cells and that the thiamine carriers are
involved in AICAr uptake in the AICAr-hypersensitive
mutants.
The Nicotinamide Riboside Transporter Nrt1 Is the Major
AICAr Transporter in Yeast—Because our results indicated
that AICAr sensitivity of the thi80, pdc2, and thi3mutants was
linked to enhanced AICAr uptake through Thi7 and Thi72, we
evaluated the effect on AICAr toxicity of mutations in the thi-
amine transporter genes. Surprisingly, knock-out of thi7 or
thi72 only very slightly increased resistance to AICAr (Fig. 6A),
thus suggesting that AICAr could be taken up by other means.
We hence explored the possible involvement of Nrt1 (previ-
ously identified as Thi71), a third transporter structurally
related to Thi7, capable of taking up thiamine with low affinity
(30) and known to be sensitive to chloroquine (29). Nrt1 is the
major transporter ofNmR (31), a precursor ofNAD(H). Knock-
out of nrt1 efficiently protected ade16 ade17 ade8 his1 cells
from toxic effects of AICAr (Fig. 6A), thus suggesting that Nrt1
is responsible for most AICAr uptake under thiamine replete
conditions (classical yeast growth media). This prediction was
directly assayed by comparing AICAR accumulation in
mutants lacking Thi7, Thi72, Nrt1, or all three transporters.
Although AICAR accumulation was only slightly affected by
the thi7 or thi72 mutations, it was strongly diminished in the
nrt1mutant and almost fully abolished in the triplemutant (Fig.
6B), thus pointing to a major role for Nrt1 in AICAr uptake.
The role ofNrt1 inAICAr uptakewas established by showing
that reintroduction of theNRT1 gene carried on a centromeric
plasmid in the septuple ade16 ade17 ade8 his1 thi7 thi72 nrt1
mutant resulted in a robust enhancement of AICAr uptake,
which was even further stimulated by overexpression of NRT1
on a multicopy plasmid (Fig. 6C). Consistently, increased
AICAr sensitivity was associated with overexpression of NRT1
(Fig. 6D), an effect that was fully reversed by amodiaquine (Fig.
6D). Finally, we established that the hypersensitivity of the thi3,
thi80, and pdc2 mutants was not dependent on Nrt1, because
these mutants were still sensitive to AICAr even in the absence
of theNRT1 gene (Fig. 6E and data not shown). Together, these
experiments establish that Nrt1 is themajor AICAr transporter
in yeast.
AICAr Uptake in Mammalian Cells—Based on our results
obtained in yeast, we wished to investigate AICAr uptake in
human cells. We first showed that addition of AICAr was suf-
ficient to trigger AICAR monophosphate accumulation in sev-
eral cells lines, although substantial disparities among them
were observed (Fig. 7A). We then used SF188 cells, in which
FIGURE 6.Nrt1 is themajor AICAr transporter in yeast. A, deletion ofNRT1 alleviates the growth defect of an ade16 ade17 ade8 his1 strain on AICAr. The cells
were grownovernight, serially diluted, and spotted on SDcasaWAUmediumcontaining or not external AICAr (5mM). All strains are in an ade16 ade17 ade8 his1
genetic background and carry the indicated additional knock-out (none, Y2950; thi7, Y8750; thi72, Y8755; nrt1, Y9116). The plates were imaged after 2 days at
37 °C. B, AICAR accumulation is severely decreased in the absence ofNRT1. Relative intracellular AICAR contents were determined onmetabolite extracts from
strains grown in SD casaWAUmedium and treated with external AICAr as in Fig. 1A. The amounts of AICAR found in the ade16 ade17 ade8 his1 strain (control,
Y2950; content set up at 1) and isogenic mutant strains nrt1 (Y9116), thi7 (Y8750), thi72 (Y8755), and thi7 thi72 nrt1 (Y9188) are presented. C, AICAr uptake
correlateswithNrt1 expression level. Triplemutant cells (thi7 thi72 nrt1; Y9188)were transformedwith vectors allowing or not () expression of theNRT1gene
(CEN, centromeric plasmid: p4980; 2, multicopy plasmid: p4926). Transformants were exponentially grown for 24 h in SDcasaWA medium, and [3H]AICAr
uptake was calculated from at least two independent kinetics. The error bars indicate variations to the mean. D, overexpression of NRT1 increases AICAr
sensitivity. The ade16 ade17 ade8 his1 strain (Y2950) was transformedwith amulticopy plasmid (p4926) allowing overexpression ofNRT1. Transformants were
grownovernight, serially diluted, and spottedonSDcasaWAmediumcontainingexternal AICAr (5mM) and in thepresenceornot of amodiaquine (AQ, 100M).
The plates were imaged after 2 days at 37 °C. E, AICAr hypersensitivity of thi80 mutant is independent to the presence of NRT1 gene. The cells were grown
overnight, serially diluted, and spotted on SDcasaWAU medium containing or not external AICAr (2 mM). All strains are in an ade16 ade17 ade8 his1 genetic
background and carry the indicated additional knock-out (thi80, Y7506; nrt1, Y9116; thi80 nrt1, Y9437). The plates were imaged after 2 days at 37 °C.
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AICAr addition resulted in a 60-fold increase in intracellular
AICAR level (Fig. 7B), to examine whether AICAR accumula-
tion was competed by addition of thiamine or NmR, which are
the substrates of yeast AICAr transporters. Clearly, neither thi-
amine nor NmR affected AICAR accumulation in SF188 cells
(Fig. 7C). By contrast, nucleosides and in particular adenosine
strongly affected AICAR accumulation (Fig. 7C), suggesting
that nucleoside transporters could be involved inAICAr uptake
in human cells. Previous work showed that dipyridamole, an
inhibitor of nucleoside uptake, could abolish the effects of
AICAr addition on neuroblastoma cells (8, 9). Indeed, we found
that dipyridamole strongly inhibited AICAR accumulation
(Fig. 7D). Accordingly, dipyridamole alleviates AICAr-induced
cytotoxic effect on SF188 cells in a dose-dependent manner
(Fig. 7E). Yeast strains each expressing one single type of human
nucleoside transporter were then used to evaluate the ability of
individual transporters to take up AICAr. Clearly, hENT1,
hENT2, and hCNT3 could efficiently take up AICAr (Fig. 7F).
These results strongly substantiate the conclusion that AICAr
uptake is mediated by nucleoside transporters in mammalian
cells.
Importantly, neither AICAR accumulation (Fig. 8A) nor
AICAR effects on cell proliferation (Fig. 8B) were affected in
AMPK1/2 double knock-out murine embryonic fibroblasts,
when compared with wild-type cells. Accordingly, AICAR tox-
icity in these cell lines was comparable and was similarly sup-
pressed by dipyridamole treatment (Fig. 8, C andD). Together,
these results demonstrate that the anti-proliferative effects of
AICAR are not AMPK-dependent.
DISCUSSION
Our screen for AICAr hypersensitive mutants in yeast
revealed that three mutations affecting the regulation of thia-
mine metabolism strongly impact on AICAR accumulation in
yeast cells. Importantly, all three mutations result in up-regu-
lation of THI7 encoding the thiamine high affinity transporter.
Our results establish that overexpression ofTHI7under control
of a heterologous promoter indeed mimics these mutants by
increasing sensitivity to AICAr and resulting in higher AICAR
intracellular concentration, yet we also show that knock-out of
THI7 or THI72 only slightly affects AICAr sensitivity in yeast,
indicating that, under standard growth conditions (when thia-
FIGURE 7. AICAr uptake occurs through adenosine transport systems in human cells. A, AICAR accumulation in various human cell lines. The cells grown
in completemediumwere treatedwith external AICAr (250M) for 12h, andmetaboliteswere extracted and separatedby liquid chromatography asdescribed
under “Experimental Procedures.” The tissular origin of the different human cell lines is as follows: SF188, pediatric glioblastoma; U87 and SF126, adult
glioblastomas; NHA/TS, immortalized astrocytes; A549, lung carcinoma; Huh7, hepatocellular carcinoma. B, SF188 cells accumulate AICAR when incubated
with AICAr. The cells were treated (red line) or not (blue line) with external AICAr (500 M) for 20 min, and metabolites were extracted and separated by liquid
chromatography. The inset corresponds to a zoom of the indicated region. AICAR content in the absence of external AICAr was set up at 1. C, effect of various
compoundson intracellular AICARaccumulation. RelativeAICAR contentwasdetermined in SF188 cells grownand treatedwith external AICAr as in Fig. 7B and
in the presence or the absence (control, set up at 1) of potential AICAr uptake competitors (100Meach) added 1min before AICAr treatment (500M, 20min).
D, dipyridamole alleviates AICAr accumulation in SF188 cells. Relative AICAR content was determined after metabolite extractions of cells grown and treated
with AICAr (500 M, 20 min) as in Fig. 7B, but in the absence (control, set up at 1) or presence of increasing concentrations of the nucleoside transporter
inhibitors dipyridamole (DP) added 1min before AICAr. E, dipyridamole protects SF188 cells against AICAr toxicity. Cell proliferation was determined by using
theWST-1 colorimetric assay on SF188 cells grown for 3 days in the absence (blue triangles) or in the presence of 0.3 mM (orange circles) or 1 mM (red circles) of
external AICAr and in the presence or not of dipyridamole. WST-1 signal obtained in the absence of both AICAR and inhibitors was set up at 1. F, expression of
the human nucleoside transporters hENT1, hENT2, and hCNT3 enhances AICAr uptake in yeast. Yeast cells (KY114 (38) expressing or not (control) the various
human nucleoside transporters (hENT1, SLC29A1; hENT2, SLC29A2; hCNT2, SLC28A2; hCNT3, SLC28A3)) were exponentially grown for 24 h in SDcasaWA
mediumprior to [3H]AICAr uptakemeasurements determined as in Fig. 4D. A–F, in all panels, values correspond to at least three independent determinations,
and error bars indicate variations to the mean.
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mine is replete), these transporters are most probably poorly
expressed and marginally contribute to AICAr uptake. We
thus tested a third transporter, named Nrt1, suspected to
contribute to thiamine uptake (30) and also identified as
sensitive to chloroquine (29), a drug that we have shown to
inhibit AICAr uptake in yeast (Fig. 5D). Clearly, deletion of
NRT1 resulted in robust resistance to AICAr and impaired
AICAR accumulation, suggesting that Nrt1, by opposition to
Thi7, is functional under standard growth conditions. We
conclude that Nrt1, the main NmR transporter in yeast (31),
is also the major AICAr transporter under standard growth
conditions.
Accumulation of intracellular AICAR in yeast and mamma-
lian cells was clearly very different. Indeed, by contrast to
human SF188 cells (Fig. 7A), no significant intracellular AICAR
accumulation was observed in wild-type yeast cells after addi-
tion of AICAr to the growth medium (Fig. 1A). This difference
between species could be due to poor AICAr uptake in yeast, to
its inefficient phosphorylation to AICAR by adenosine kinase,
and/or to vigorous AICAR metabolization to IMP by ATIC.
Indeed, mutations in the yeast ATIC coding genes resulted in a
drastic enhancement of AICAR accumulation (Fig. 1C), thus
indicating that the low AICAR accumulation in the wild-type
strain was, in part, due to its efficient metabolization to IMP by
ATIC. By contrast, this also suggested that AICAR accumula-
tion inmammalian cells results from the fact that ATICwas not
active enough to metabolize all the AICAR synthesized from
the precursor. The steady state AICAR accumulation, which
reflects the balance between AICAr entry and utilization, var-
ied significantly from one cell line to another (Fig. 7A). Impor-
tantly, in human SF188 cells, AICAr uptake was not affected by
thiamine or NmR but instead was decreased in the presence of
nucleosides in the growth medium. Accordingly AICAR accu-
mulation was inhibited by dipyridamole, an inhibitor of aden-
osine transport, and dipyridamole significantly reduced the
effect of AICAr on cell proliferation, as previously reported for
undifferentiated human neuroblastoma cells (SH-SY5Y) (9).
We identified three nucleoside transporters, namely hENT1,
hENT2, and hCNT3, as AICAr transporters. The nucleoside
transporters constitute a multiprotein family with two sub-
groups (32): SLC28A (three members, hCNT1–3) and SLC29A
(four members, hENT1–4), with each transporter presenting
various substrate specificity and sensitivity to inhibitors (32).
The remaining members of the family were not able to stimu-
late AICAr uptake in yeast (hCNT1 and hCNT2, Fig. 7F) or are
unlikely to play amajor role in AICAr uptake. Indeed, hENT3 is
a lysosomal protein, and hENT4 is highly resistant to dipyrida-
mole (33). By contrast, yeast cells do not have a dedicated
adenosine transport system and can only inefficiently take
up adenosine (34). Interestingly thiamine is known to
strongly interfere with adenosine uptake in yeast (27), as well
as with entry of the nucleoside analog cordicepin (27). Thus,
yeast thiamine transporters are thought to be responsible for
most of adenosine uptake and are also involved in AICAr
uptake (Fig. 6B). Importantly, AICAr uptake in yeast is far
less efficient than it is in mammalian cells. Indeed, a 10-fold
higher concentration of extracellular AICAr was required in
yeast cells (5 mM) compared with human and mouse cells
(0.5 mM) to achieve comparable levels of intracellular AICAR
accumulation. The yeast and human AICAr uptake systems
thus appear clearly distinct. In addition, the yeast AICAr
transporter Nrt1 does not have any identified ortholog in
human cells (31), and neither the SLC19A2 nor the SLC19A3
human thiamine transporters (35, 36) enhanced AICAr
uptake when expressed in yeast.4 However, despite these dif-
ferences, AICAr uptake occurs through adenosine transport
systems in both yeast and human cells.
Importantly, our results also demonstrate that AICAR accu-
mulation is normal in AMPK1/2 KO embryonic fibroblasts.
In addition, the anti-proliferative effects of AICAR are not
affected in the same cells. Thus, these effects are not AMPK-
dependent. This result is in good agreement with recently pub-
lished work by others (37) and uncovers the acute necessity to
4 M. Moenner and B. Pinson, unpublished results.
FIGURE 8. AICAr uptake and AICAR toxicity are AMPK-independent in
mouse fibroblasts. A, the AMPK catalytic subunits 1 and 2 are not
required for AICAR accumulation in MEFs. Relative AICAR content was deter-
mined in MEF double knock-out (AMPK KO stands for AMPK1/2 KO) or
not (AMPK WT) in AMPK genes. The cells were grown and treated with
external AICAr as in Fig. 7B and in thepresence (DP) or the absence (DP) of
dipyridamole (2.5M) added 1min before AICAr treatment (500M, 20min).
AICAR contentwas set upat 1 forWTMEF in the absenceofDP.B, AICAReffect
on cell proliferation is not altered in the absenceofAMPK-1 and -2 catalytic
subunits. Cell proliferation was measured using WT cells (red curves) or
AMPK1/2 KO cells (green curves) MEF grown for 3 days in the presence
(squares) or the absence (triangles) of AICAr (1 mM). C and D, dipyridamole
protects MEF against AICAr toxicity in an AMPK-independent manner. Cell
proliferation was determined using the WST-1 test on wild-type and AMPK
KOMEFs grown for 3 days in the absence (blue triangles) or in the presence of
either 0.3 mM (orange circles) or 1 mM (red circles) of external AICAr and in the
presence or not of dipyridamole. A–D, in all panels, values correspond to at
least three independent determinations, and errors bars indicate variations to
the mean.
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identify the AICAR targets that are critical for its anti-prolifer-
ative effects.
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